An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
At a glance
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
- Primary source
- MarketWatch.com - Top Stories — Read original article
- Published
- Topic
- Finance
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
This summary comes from MarketWatch.com - Top Stories. Read the full article at the original source.
References
More in Finance
As ‘Spider-Man’ joins ‘The Odyssey’ in Imax, are premium movie screens worth the extra price?
Some movie fans call premium screenings a “gimmick.” Others are driving six hours to see “The Odyssey” in Imax 70mm.
These are the stocks posting the largest moves after the bell.
This indicator is giving the bull market another lease on life
Stock-market timers recently rushed to the exits, which is bullish from a contrarian perspective.
Traders in the world’s most important financial market are bracing for a wild stretch ahead
Volatility is ticking higher in the $30 trillion Treasury market as investors bet that yields will push higher.